Transcription factor MEF2D regulates aberrant expression of ACSL3 and enhances sorafenib resistance by inhibiting ferroptosis in HCC

Transcription factor MEF2D regulates aberrant expression of ACSL3 and enhances sorafenib resistance by inhibiting ferroptosis in HCC

BackgroundSorafenib is a first-line treatment for hepatocellular carcinoma (HCC); however, acquired resistance often results in a poor prognosis, indicating a need for more effective therapies. Sorafenib induces cell death through an iron-dependent mechanism known as ferroptosis, which is closely as...

Full description

Saved in:
Bibliographic Details
Main Authors: Xue Li, Shimin Chen, Yuanyuan Shi, Yuanjing Wang, Xuanzhe Wang, Qian Lin, Chao Wu, Wenshuo Fang, Peng Sun, Leina Ma
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-12-01
Series:Frontiers in Pharmacology
Subjects:
ACSL3
MEF2D
HCC
ferroptosis
sorafenib resistance
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2024.1464852/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items